Product Code: RP-ID-10085102 |
Published Date: 21 Oct 2022 |
Region: NA |
Category: Healthcare & Pharmaceuticals |
Report ID: 10085102
Market Overview:
Global CRISPR Technology Market Size study, by Product and Services (CRISPR Products and CRISPR services) Application (biomedical applications, agricultural applications, industrial applications and biological research) End-User (includes pharmaceutical and biopharmaceutical companies, biotechnology companies, academic & research institutes and contract research organizations) and Regional Forecasts 2018-2025.
Global CRISPR Technology Market valued approximately USD 449.6 million in 2017 is anticipated to grow with a healthy growth rate of more than 25 % over the forecast period 2018-2025. Increasing availability of government and private funding and growing adoption of CRISPR technology are some key trends that are responsible for the wide adoption of CRISPR Technology globally. As per the Congressional Research Service (US), CRISPR-related research funding by National Institutes of Health (NIH) grew from $5.1 million in FY2011 to $603 million in FY2016, such high funding in the CRISPR has set the scientific foundation for advanced gene editing technologies such as CRISPR-CAS 9. Moreover, between the periods of 2006-2016 (FY) as per National Institute of Health (NIH) approximately $981 million was funded by the NIH for CRISPR related researches. Further in 2017, as per the Defense Advanced Research Projects Agency (DARPA), the DARPA has announced to invest $65 million over the course of next four years till 2021 in order to make CRISPR Gene Editing Safer and to counter bioterrorism threats. According to Pharmaceutical Research and Manufacturers of America (PhRMA), the biopharmaceutical R&D expenditure in the United States grew in 2014 was ~$53.5 billion which grew up-to $58.8 billion in 2015. Similarly, according to the Gov.UK in 2017, UK government recently opened its doors to develop drug discovery by investing around $7.16 million that would help businesses to meet and understand the challenges involved in developing drugs. By use of CRISPR, several drugs can be developed which can enhance the effectiveness and quality of medicines and vaccines available in the market for various blood disorders and heart diseases. As a result, the adoption of CRISPR technology would increase thereby, aiding the growth of the market. However, high cost associated with CRISPR technology and presence of alternative technologies are the major factors that impede the growth of global CRISPR Technology market.
The leading market players mainly include-
Thermo Fisher Scientific
Merck KGaA
GenScript
Integrated DNA Technologies (IDT)
Horizon Discovery Group
Agilent Technologies
Cellecta, Inc.
GeneCopoeia, Inc.
New England Biolabs
Origene Technologies, Inc.
On the basis of segmentation, the CRISPR technology market is segmented into product & services, application and end-users. The product & services segment of global CRISPR technology market is classified into CRISPR Products and CRISPR services of which CRISPR services segment is expected to emerge as the fastest growing segment. Based on application segment, the CRISPR technology market is diversified into biomedical applications, agricultural applications, industrial applications and biological research of which biomedical application segment holds the largest market share owing to the growing application in drug discovery applications. The end-user segment includes pharmaceutical and biopharmaceutical companies, biotechnology companies,
academic & research institutes and contract research organizations.
The regional analysis of CRISPR technology market is considered for the key regions such as North America, Europe, Asia Pacific, Latin America and ROW. North America have occupied major share in the global CRISPR Technology market. The major reasons for the dominance of North America are increasing government and private funding, the adoption of CRISPR in several applications and presence of major pharma and gene therapy companies. Whereas, Asia-Pacific is expected to emerge as the fastest growing region in terms of market share. The growth of Asia-Pacific region is witnessed owing as China had registered nine clinical trials based on CRISPR-edited cells on various diseases such as HIV infection and cancers and ongoing researchers to support CRISPR technology.
The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming eight years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within each of the regions and countries involved in the study. Furthermore, the report also caters the detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, the report shall also incorporate available opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:
By Product and services:
CRISPR Products
CRISPR Enzymes
CRISPR Libraries
CRISPR Kits
Other CRISPR Products
CRISPR Services
gRNA Design & Vector Construction
Cell Line Engineering
Screening Services
Other CRISPR Services
By Application:
Biomedical Applications
Agricultural Applications
Industrial Applications
Biological Research
By End-user:
Pharmaceutical and Biopharmaceutical Companies
Biotechnology Companies
Academic & Research Institutes
Contract Research Organizations
By Regions:
North America
U.S.
Canada
Europe
UK
Germany
ROE
Asia Pacific
China
India
Japan
ROAPEC
LAMEA
Brazil
Mexico
ROW
Middle East & Africa
Furthermore, years considered for the study are as follows:
Historical year – 2015, 2016
Base year – 2017
Forecast period – 2018 to 2025
Target Audience of the Global CRISPR Technology Market in Market Study:
Key Consulting Companies & Advisors
Large, medium-sized, and small enterprises
Venture capitalists
Value-Added Resellers (VARs)
Third-party knowledge providers
Investment bankers
Investors
Merck KGaA
GenScript
Integrated DNA Technologies (IDT)
Horizon Discovery Group
Agilent Technologies
Cellecta, Inc.
GeneCopoeia, Inc.
New England Biolabs
Origene Technologies, Inc.
Related Reports
Proof of Quality & Reliability
